Coherus Oncology Résultats passés
Passé contrôle des critères 0/6
Coherus Oncology a connu une croissance annuelle moyenne de ses bénéfices de 10.4%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 33.8% par an. Les revenus ont augmenté de en baisse à un taux moyen de 27.3% par an.
Informations clés
10.44%
Taux de croissance des bénéfices
19.32%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.04% |
| Taux de croissance des recettes | -27.31% |
| Rendement des fonds propres | -219.61% |
| Marge nette | -368.28% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • May 16
CHRS: Anti Tumor Readouts Will Shape Future Revenue Visibility And Profitability
Analysts have raised their fair value estimate for Coherus Oncology stock from $10.00 to $12.00, citing Guggenheim's recent initiation focused on the company's anti tumor potential as a key driver behind the updated price target and more optimistic assumptions around revenue growth, profit margins, and future P/E. Analyst Commentary Analysts pointing to the anti tumor opportunity see the recent fair value move to US$12.00 as a sign that expectations for the stock are improving, particularly in how the market might value future oncology revenue and profitability.
Mise à jour du récit • Apr 29
CHRS: Lock Ups And Recent Equity Raise Will Shape Bullish Outlook
Analysts have adjusted their price target on Coherus Oncology to $6.75, reflecting updated views on discount rates, profit margin assumptions, and future P/E expectations, while keeping the fair value estimate unchanged at $6.75. What's in the News Lock up agreements on certain stock options of Coherus Oncology, Inc.
Mise à jour du récit • Apr 15
CHRS: Upcoming Readouts And New Outperform Coverage Will Shape Oncology Upside
Analysts have lifted their price target on Coherus Oncology to $4.00, citing updated expectations for revenue growth, profit margins, and a slightly higher future P/E multiple informed by recent bullish research and new Outperform coverage ahead of key readouts. Analyst Commentary Recent research points to growing interest in Coherus Oncology as analysts respond to fresh coverage ahead of key clinical readouts.Mise à jour du récit • Apr 01
CHRS: Upcoming Readouts And Equity Raises Will Shape Oncology Outlook
Analysts have lifted their price target on Coherus Oncology to $6.75, highlighting higher assumed revenue growth of 64.35%, a stronger profit margin of 14.76% and a modestly lower future P/E of 55.41x, following fresh bullish coverage ahead of key readouts. Analyst Commentary Bullish Takeaways Bullish analysts see the new coverage and price target as a vote of confidence in Coherus Oncology's ability to convert its pipeline into revenue growth, reflected in the 64.35% revenue growth assumption built into current models.Mise à jour du récit • Mar 18
CHRS: Upcoming Readouts And Biomarker Data Will Support Stronger Oncology Outlook
Analysts have raised their price target on Coherus Oncology to $4.00, presenting the unchanged fair value in conjunction with a lower discount rate and significantly higher modeled revenue growth, while citing recent bullish initiation and Outperform ratings ahead of key readouts. Analyst Commentary Recent research coverage frames Coherus Oncology as a higher risk, higher reward idea, with enthusiasm around upcoming readouts balanced by concerns about execution and the durability of modeled revenue growth.Mise à jour du récit • Mar 03
CHRS: Upcoming Readouts And New Collaboration Will Shape Oncology Pipeline Outlook
Analysts have kept their average $6.75 price target on Coherus Oncology steady, as recent bullish coverage and Outperform initiations are balanced by updated assumptions that include a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts highlight that fresh Outperform initiations signal confidence that the current share price already reflects more cautious margin and P/E assumptions.Seeking Alpha • Feb 20
Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114
Summary Coherus Oncology is downgraded to 'Hold' due to underwhelming LOQTORZI sales and reliance on upcoming pipeline catalysts. CHRS pivots focus to CHS-114, an anti-CCR8 antibody, and casdozokitug, with multiple phase 1b/2a data readouts expected in 2026. Initial biomarker data for CHS-114 in HNSCC shows strong target depletion and TME remodeling, but clinical efficacy needs to be proven further. Cash runway was limited to 12 months; however, the company closed an offering, raising approximately $50.1 million to further fund its pipeline. Read the full article on Seeking AlphaMise à jour du récit • Feb 17
CHRS: Upcoming Clinical Readouts Will Drive Reassessment Of Oncology Pipeline Potential
Analysts have raised their price target on Coherus Oncology from about $5.67 to $6.75, citing updated assumptions on revenue trends, margins, and future P/E following recent bullish coverage and the initiation of coverage on the name ahead of key clinical readouts. Analyst Commentary Bullish Takeaways Bullish analysts point to upcoming clinical readouts as a key potential catalyst that could help support the higher price target and justify updated P/E assumptions.Mise à jour du récit • Feb 03
CHRS: Upcoming Readouts Will Shape Revenue Visibility And Profitability Expectations
Analysts have raised their fair value estimate for Coherus Oncology from US$7.00 to US$10.00, citing a more constructive view on revenue trends, profitability and future P/E assumptions following recent bullish coverage ahead of key readouts. Analyst Commentary Recent research coverage has leaned positive, with bullish analysts pointing to a more constructive setup around upcoming clinical readouts and the valuation reset implied by the higher fair value estimate.Mise à jour du récit • Jan 20
CHRS: Future Biomarker And Index Inclusion Catalysts Will Support Stronger Oncology Outlook
Analysts have made a slight adjustment to their price target on Coherus Oncology to reflect updated assumptions around discount rate, revenue growth, and margins, while maintaining their fair value estimate at approximately $4.00 per share. What's in the News Coherus Oncology published preclinical and clinical biomarker research in Molecular Cancer Therapeutics on its anti CCR8 monoclonal antibody, now named tagmokitug, highlighting high selectivity, picomolar binding affinity and effector mediated killing of CCR8+ cells, with no off target binding reported (Molecular Cancer Therapeutics, December 2025).Article d’analyse • Jan 10
There's No Escaping Coherus Oncology, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 27% Share Price Rise
Coherus Oncology, Inc. ( NASDAQ:CHRS ) shareholders would be excited to see that the share price has had a great month...Mise à jour du récit • Jan 06
CHRS: Future Immune Activation And Biomarker Data Will Support Stronger Oncology Outlook
Analysts have maintained their price target for Coherus Oncology at US$4.00, citing updates to revenue decline assumptions, a slightly lower discount rate, a small improvement in projected profit margins, and a reduced future P/E multiple as the key drivers of the refreshed view. What's in the News Publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics on tagmokitug, an investigational anti-CCR8 monoclonal antibody with high selectivity and picomolar binding affinity targeting CCR8+ T regulatory cells in solid tumors (Molecular Cancer Therapeutics).Mise à jour du récit • Dec 13
CHRS: Future Immune Activation Data Will Support Stronger Oncology Outlook
Analysts have raised their price target for Coherus Oncology to approximately 4.00 dollars from about 1.10 dollars, citing a less severe expected revenue decline, a slight improvement in projected profit margins, and a marginally higher future earnings multiple, despite a modestly increased discount rate. What's in the News New multiomic tumor and blood biomarker data from the Phase 1b dose expansion arm of CHS-114 in recurrent or metastatic head and neck squamous cell carcinoma show significantly enhanced and sustained immune activation when combined with toripalimab (Key Developments).Article d’analyse • Nov 14
Revenues Working Against Coherus Oncology, Inc.'s (NASDAQ:CHRS) Share Price Following 26% Dive
The Coherus Oncology, Inc. ( NASDAQ:CHRS ) share price has softened a substantial 26% over the previous 30 days...Mise à jour du récit • Sep 11
Upcoming Clinical Data Will Reshape Immuno-Oncology Amid Uncertainties
Despite a decline in net profit margin, Coherus Oncology's significantly higher future P/E ratio reflects increased investor optimism, resulting in a raised consensus price target from $4.70 to $5.67. What's in the News Coherus Oncology received a deficiency notice from Nasdaq after its common stock closed below $1.00 per share for 30 consecutive business days, putting it at risk of delisting.Article d’analyse • Aug 10
Industry Analysts Just Upgraded Their Coherus Oncology, Inc. (NASDAQ:CHRS) Revenue Forecasts By 21%
NasdaqGM:CHRS 1 Year Share Price vs Fair Value Explore Coherus Oncology's Fair Values from the Community and select...Article d’analyse • Jul 24
Coherus Oncology, Inc.'s (NASDAQ:CHRS) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Those holding Coherus Oncology, Inc. ( NASDAQ:CHRS ) shares would be relieved that the share price has rebounded 35% in...Article d’analyse • May 18
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues
The Coherus BioSciences, Inc. ( NASDAQ:CHRS ) share price has fared very poorly over the last month, falling by a...Article d’analyse • May 15
Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates
Market forces rained on the parade of Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shareholders today, when the analysts...Seeking Alpha • Apr 17
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs
Summary Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hepatocellular carcinoma with a 17.2% complete response rate in phase 1 and is now in a phase 2 study. CHRS is still marketing Loqtorzi for nasopharyngeal carcinoma, with Q4'24 revenues of $7.5M representing 29% growth over the prior quarter. Read the full article on Seeking Alpha
Nouveau récit • Apr 03
UDENYCA Divestiture And LOQTORZI Progress Will Forge Opportunity Amid Risks
UDENYCA divestiture and headcount reduction will strengthen the balance sheet and improve margins through reduced expenses.Article d’analyse • Mar 28
Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop
To the annoyance of some shareholders, Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shares are down a considerable 27% in...Article d’analyse • Mar 24
Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings
Strong earnings weren't enough to please Coherus BioSciences, Inc.'s ( NASDAQ:CHRS ) shareholders over the last week...Article d’analyse • Dec 21
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise
Despite an already strong run, Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shares have been powering on, with a gain of...Seeking Alpha • Dec 16
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Summary Coherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS holds $97.7 million in cash, $36.6 million in term loans, and $227.9 million in convertible notes, with $70.8 million in net revenues. CHRS is divesting their Udenyca franchise for $483.4 million, with potential milestone payments, following previous sales of Cimerli and Yusimry franchises. CHRS's financial and strategic moves indicate a cautious yet potentially rewarding horizon for investors. Read the full article on Seeking AlphaArticle d’analyse • Nov 06
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%
To the annoyance of some shareholders, Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shares are down a considerable 30% in...Article d’analyse • Sep 22
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Unfortunately for some shareholders, the Coherus BioSciences, Inc. ( NASDAQ:CHRS ) share price has dived 27% in the...Seeking Alpha • Aug 13
Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Summary Coherus BioSciences, Inc. focuses on biosimilars and immuno-oncology treatments, with LOQTORZI and UDENYCA as key products. Coherus BioSciences' biosimilar IP shows potential for profitability, with strategic divestitures impacting its financial position post Q3 2024. UDENYCA drives most of CHRS's revenues, positioning it as its crown jewel with a 29% market share and strong payer coverage. The success of UDENYCA and the potential growth from LOQTORZI are critical to avoiding dilution risks and ensuring long-term financial stability. Despite some cash runway concerns, CHRS trades at a low valuation, so it leans towards a speculative “buy” for investors who understand the embedded biotech risks. Read the full article on Seeking AlphaArticle d’analyse • Aug 07
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 0.5x Coherus BioSciences, Inc. ( NASDAQ:CHRS ) is...Seeking Alpha • May 31
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
Summary Coherus BioSciences, Inc. is relying on revenues from existing drugs and its developmental pipeline after selling off a major source of revenue in Cimerli. CHS-114, an anti-CCR8 antibody being developed by CHRS, is set to produce data at the ASCO 2024 Annual Meeting. Coherus BioSciences refers to Yusimry (a biosimilar Humira) as a non-core product, and could look to sell the drug, although revenues are growing. Read the full article on Seeking AlphaArticle d’analyse • May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now
Key Insights Coherus BioSciences to hold its Annual General Meeting on 29th of May Total pay for CEO Denny Lanfear...Seeking Alpha • Mar 21
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Summary CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point to a strong Q1'24 for Udenyca, which could increase the market's confidence that CHRS can offset lost revenues from the Cimerli sale. CHRS has data in H1'24 from a phase 1 trial of its anti-CCR8 antibody, CHS-114, in solid tumors, adding a catalyst to the calendar. Read the full article on Seeking AlphaArticle d’analyse • Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Unfortunately for some shareholders, the Coherus BioSciences, Inc. ( NASDAQ:CHRS ) share price has dived 29% in the...Seeking Alpha • Jan 17
Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Summary CHRS has a pipeline of biosimilars including Yusimry, Cimerli, and Udenyca. A new form of Udenyca, Udenyca Onbody, was approved in December 2023. CHRS also has a new drug Loqtorzi (toripalimab) which was approved in the US for the treatment of nasopharyngeal carcinoma in October 2023. Approval of Loqtorzi is a key step towards creating a revenue source with a greater moat versus biosimilars. Read the full article on Seeking AlphaArticle d’analyse • Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.1x Coherus BioSciences, Inc. ( NASDAQ:CHRS ) is...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Coherus Oncology gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 47 | -173 | 93 | 106 |
| 31 Dec 25 | 42 | -183 | 96 | 109 |
| 30 Sep 25 | 278 | 61 | 140 | 100 |
| 30 Jun 25 | 272 | 59 | 145 | 95 |
| 31 Mar 25 | 32 | -195 | 111 | 88 |
| 31 Dec 24 | 26 | -215 | 115 | 92 |
| 30 Sep 24 | 110 | -249 | 133 | 94 |
| 30 Jun 24 | 179 | -242 | 148 | 101 |
| 31 Mar 24 | 227 | -230 | 170 | 100 |
| 31 Dec 23 | 257 | -238 | 186 | 106 |
| 30 Sep 23 | 211 | -217 | 192 | 112 |
| 30 Jun 23 | 182 | -264 | 193 | 129 |
| 31 Mar 23 | 183 | -271 | 195 | 151 |
| 31 Dec 22 | 211 | -292 | 198 | 199 |
| 30 Sep 22 | 239 | -279 | 195 | 221 |
| 30 Jun 22 | 276 | -230 | 190 | 229 |
| 31 Mar 22 | 304 | -210 | 179 | 246 |
| 31 Dec 21 | 327 | -287 | 170 | 363 |
| 30 Sep 21 | 364 | -232 | 157 | 357 |
| 30 Jun 21 | 395 | -165 | 149 | 342 |
| 31 Mar 21 | 443 | -76 | 143 | 310 |
| 31 Dec 20 | 476 | 132 | 139 | 143 |
| 30 Sep 20 | 489 | 162 | 137 | 192 |
| 30 Jun 20 | 487 | 181 | 137 | 153 |
| 31 Mar 20 | 435 | 145 | 140 | 127 |
| 31 Dec 19 | 356 | 90 | 137 | 94 |
| 30 Sep 19 | 232 | -12 | 135 | 0 |
| 30 Jun 19 | 121 | -118 | 128 | 0 |
| 31 Mar 19 | 37 | -185 | 110 | 0 |
| 31 Dec 18 | 0 | -209 | 94 | 106 |
| 30 Sep 18 | 0 | -196 | 75 | 0 |
| 30 Jun 18 | 0 | -196 | 64 | 0 |
| 31 Mar 18 | 1 | -208 | 67 | 0 |
| 31 Dec 17 | 2 | -238 | 69 | 0 |
| 30 Sep 17 | 2 | -265 | 69 | 0 |
| 30 Jun 17 | 165 | -122 | 69 | 0 |
| 31 Mar 17 | 178 | -137 | 59 | 0 |
| 31 Dec 16 | 190 | -127 | 52 | 0 |
| 30 Sep 16 | 199 | -104 | 47 | 0 |
| 30 Jun 16 | 44 | -259 | 44 | 0 |
| 31 Mar 16 | 37 | -248 | 41 | 0 |
| 31 Dec 15 | 30 | -223 | 36 | 0 |
| 30 Sep 15 | 26 | -200 | 30 | 0 |
| 30 Jun 15 | 35 | -137 | 24 | 0 |
Des revenus de qualité: CHRS n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: CHRS n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CHRS n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 10.4% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de CHRS au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: CHRS n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 43% ).
Rendement des fonds propres
ROE élevé: CHRS a un retour sur capitaux propres négatif ( -219.61% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/26 01:54 |
| Cours de l'action en fin de journée | 2026/05/26 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Coherus Oncology, Inc. est couverte par 14 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Colleen Kusy | Baird |
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |